Kornimate/medical-research-clean huggingface dataset:
comparison of hemodynamic effect between the spinal anesthesia and saddle block using levobupivacaine during transurethral resection of the prostate in cardiac elderly patients

Conditions: TURP Syndrome; Spinal Anesthesia

Summary: transurethral resection of the prostate (turp) is the most common surgical intervention for patients with benign prostatic hyperplasia. turp is mostly applied to elderly patients with hypertension and problems with breathing, circulation system, and kidney functions; therefore, it becomes very important to keep a stable anesthesia that will minimize the hemodynamic differences in these patients. general anesthesia causes more hemodynamic differences than regional anesthesia. thus, regional anesthesia is highly preferable in turp applications.

turp is performed by inserting a resectoscope through the urethra and resecting prostatic tissue with an electrically powered cutting-coagulating metal loop or using laser-22 vaporization energy. this can be accomplished with either a monopolar turp (m-turp) or bipolar turp (b-turp) technique. laser energy for turp has also been used for many years. with each technique, as much prostatic tissue as possible is resected, but the prostatic capsule is usually preserved. if the capsule is violated, large amounts of irrigation solution can be absorbed into the circulation via the periprostatic, retroperitoneal, or peritoneal space. bleeding during turp is not uncommon but usually controllable; hemostasis becomes difficult when large venous sinuses are opened. if the bleeding becomes uncontrollable, the procedure should be terminated as quickly as possible, and a foley catheter should be passed into the bladder and traction applied to it. the catheter's inflated balloon exerts lateral pressure on the prostatic bed and reduces bleeding. bleeding requiring transfusion occurs in approximately 2.5% of turp procedures.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists (asa) iii, * with ischemic heart disease (history of myocardial ischemia, * a history of a positive treadmill test result (electro cardio graph stress test), * use of nitroglycerin, chronic stable angina for more than two months, or an ecg with abnormal q waves), with ejection fraction (ef) 35%-50%, exclusion criteria: * patients under 65 years, * patients with any diseases that increase intraabdominal pressure (any intra-abdominal mass), * general contraindications of spinal anesthesia as patient refusal, coagulation disorders, local infection at the site of the block, psychiatric illness,
evaluating the efficacy of convalescent plasma in symptomatic outpatients infected with covid-19

Conditions: COVID-19

Summary: this study will provide investigational convalescent plasma for patients infected with the sars-cov-2 with mild to moderate symptoms who meet inclusion criteria as judged by physician evaluation.

this study will provide investigational convalescent plasma for patients infected with the sars-cov-2 with mild to moderate symptoms who meet inclusion criteria as judged by physician evaluation. following patient enrollment into the study, completion of informed consent and randomization, the patient will receive one unit of convalescent covid plasma or standard of care. the plasma will be infused in an outpatient infusion center by highly trained and experienced staff. vitalant will be providing the plasma as per their normal screening and distribution protocols. patients will be monitored for safety during the infusion and per protocol following the infusion for a period of 28 days. primary efficacy and safety endpoints will be statistically analyzed and compared between the two groups.

Eligibility criteria:
inclusion criteria: * laboratory confirmed diagnosis of infection with sars-cov-2 * symptoms of covid -19 - cough, fever, sore throat, sob, anosmia, diarrhea, myalgia * symptoms less than 14 days * id physician determination that the patient does not need hospitalization * o2 saturation of \>93% * informed consent provided by the patient or healthcare proxy * age ≥ 18 years * ambulatory outpatient when informed consent obtained and study drug is administered exclusion criteria: * age \< 18 y/o * patients currently receiving intravenous immunoglobulin * hypercoagulable state - neoplasia, collagen vascular disease, myelodysplastic syndrome, chronic anticoagulation treatment, etc. * need to be hospitalized * o2 sat \< 93% * d-dimer \> 2x normal * chronic oxygen therapy * renal insufficiency with creatinine clearance \< 30 * long term care or assisted living facility resident * ongoing usage of hydroxychloroquine for any indication * history of blood or plasma transfusion related complications * enrollment into any other investigational drug or device study within the previous 30 days * any drug, chemical or alcohol dependency as determined by the investigator through history that may affect study procedures and follow up * pregnant or breast feeding * any acute or chronic medical comorbidity, psychiatric, social or other circumstance that, in the opinion of the investigator, may interfere with study compliance, completion, or accurate assessment of the study outcomes/safety * admitted to or expected to be admitted to a medical facility

Keywords: convalescent plasma
qingfei granule for the treatment of the pediatric acute upper respiratory tract infection with bacterial infection

Conditions: Upper Respiratory Tract Infection; Bacterial Infection; Chinese Medicine; Pediatric Acute Upper Respiratory Tract Infection

Summary: the study aims to assess the antibacterial effect and symptoms-relief of qingfei granule in the patients with pediatric acute upper respiratory tract infection with bacterial infection.

upper respiratory tract infection is the most common respiratory disease in childhood, and the incidence rate accounts for more than 60% of pediatric outpatients, ranking first in pediatric diseases. at present, antibiotics are commonly used to treat children with upper respiratory tract infections. however, due to the large amount of clinical use of antibiotics in recent years, the resistance of various pathogens has become stronger and stronger, which has caused the majority of clinicians and researchers to turn their attention to traditional chinese medicine. qingfei granule is composed of six common herbal medicines such as schizonepeta (jing-jie),radix scutellariae (huang-qin),forsythia (lian-qiao), etc. after upper respiratory tract infections with bacterial infections, chills, fever, runny nose, red and sore throat may occur, and may be accompanied by mild cough, thin red tongue, yellow moss, floating pulse,which is considered as the exogenous wind-heat zheng in chinese medicine. the study aims to assess the antibacterial effect and symptoms-relief of qingfei granule in the patients with pediatric acute upper respiratory tract infection with bacterial infection.

Eligibility criteria:
inclusion criteria: 1. diagnosis with the acute upper respiratory tract infection; 2. diagnosis with wind-heat zheng according to chinese medicine; 3. age: 5-14 years old; 4. body temperature ≥ 37.5 ℃; 5. white blood cell count\> 12 × 10\^9 / l, and / or neutrophil ratio over than 70%; 6. the informed consent process complies with the regulations, and the legal agent or the child (≥8 years old) jointly sign the informed consent exclusion criteria: (1) acute bacterial otitis media; (2) patients with periodontitis or periodontal abscess (3) candidiasis; (4) patients with positive mycoplasma; (5) taking antibiotics, anti-inflammatory drugs, and antihistamines; (6) patients with severe comorbidities of heart, liver and kidney; (7) other patients with acute infectious diseases and mycoplasma pneumoniae infections with symptoms similar to upper respiratory tract infection; (8) children with a history of epilepsy or convulsions; (9) patients with mental illness; (10) those who are allergic to treatment drugs; (11) participated in other clinical trials in the past month; (12) the investigator evaluates that it is not suitable to participate in this clinical trial or according to the investigator's judgment, who is likely to loss to follow-up. -
mindful movement and breathing to improve outcomes of gynecologic surgery

Conditions: Gynecologic Malignancy; Abdominal Surgery by Laparotomy; Pain; Psychological Distress; Lung Function; Surgical Complications

Summary: the purpose of this clinical trial is to understand if women undergoing surgery for a suspected gynecologic malignancy are interested in participating in a mindful movement and breathing program and what the effects of this program are on women and the surgery-related symptoms they experience. mindful movement and breathing programs may be effective for easing distress, post-surgical pain, and other symptoms of surgical procedures.


Eligibility criteria:
inclusion criteria: * signed protocol specific informed consent * 18 years of age or older * scheduled for a major abdominal gynecological surgery to remove a mass that is suspected to be malignant exclusion criteria: * unable to read or understand english * cognitively impaired and/or cannot complete interviews as judged by the referring physician, nurse, or study staff
a novel assay to quantify treatment response in cystic fibrosis (cf)

Conditions: Cystic Fibrosis

Summary: inflammation is present in the cystic fibrosis (cf) airway from the time of infancy, and worsens with the onset of chronic infection. therapies with proven benefit are associated with decreased airway inflammation. thus, sensitive and reproducible biomarkers of airway inflammation have long been sought as a necessary component to improved clinical care and to facilitate therapeutic trials for cf. fev1, the standard outcome measure in cf, is recognized as an insensitive outcome measure. the investigators have identified a panel of 10 genes which sensitively predict resolution of pulmonary inflammation, in response to therapy of an acute pulmonary exacerbation. with the goal of yielding a technically simple but unique cf biomarker assay, the investigators have tested whether proteins signified by these genes show large changes in expression following treatment of acute pulmonary exacerbations. protein quantifications are among the most common measurements performed in clinical laboratories around the world. based on preliminary findings that changes in white blood cell proteins mirror changes seen in the genes, the investigators propose to identify top candidate proteins, from the investigators gene panel, which change in response to exacerbation therapy. once identified, these proteins will be quantified directly with a new blood test which is inexpensive and simple to perform. the investigators propose to validate this blood test in a single site trial. if successful, this proposal will yield a biomarker assay that will be available to validate in a multi-site trial and provide unique insights into mechanisms that regulate white blood cell activation and recruitment in cf lung disease.


Eligibility criteria:
inclusion criteria: 1. documented diagnosis of cf. 2. age 18 years old or greater. 3. presentation at the start of treatment for a pulmonary exacerbation of cf. 4. ability to perform reproducible pulmonary function tests and produce sputum. 5. willingness to comply with study procedure and willingness to provide written consent. exclusion criteria: 1. presence of a condition or abnormality that, in the opinion of the principal investigator (pi), would compromise the safety of the patient or the quality of the data. 2. use of systemic steroids
early gastric decompression during advanced cardiopulmonary resuscitation (egd_acls)

Conditions: Out-of-Hospital Cardiac Arrest

Summary: this study aimed to identify the effect of early gastric decompression on the improvement of circulation in arrest patients during cardiopulmonary resuscitation at the clinical setting of emergency department.

subjects and setting : adult sudden cardiac arrest patients in out of hospital, and transported to emergency department for advanced resuscitation treatment interventions: first step, establish the advanced airway, after then insertion the naso (or oro)-gastric tube during cpr data collection: live observation and review the automatically recoding data missing or failed data should be collected and descriped study period and sample size: numbers of participants necessary to identify the effect of interventions; 12 months or lesser were anticipated analysis: all collected data can be analysed by statistical programs

Eligibility criteria:
inclusion criteria: * out of cardiac arrest patients who was transported to the emergency department for advanced resuscitation care exclusion criteria: * do not attempted * inevitable death cofirmed at emergency department * early recovery of spontaneous circulation before the intervention or sufficient collections of outcome data * data loss * others

Keywords: cardiopulmonary resuscitation gastric emptying
a study of multiple sclerosis routine clinical practice: impact on adherence and clinical outcomes of ofatumumab treated patients

Conditions: Multiple Sclerosis, Relapsing-Remitting

Summary: this was a retrospective non-interventional study (nis) of adult (≥18 years) multiple sclerosis (ms) patients on ofatumumab therapy in the united kingdom (uk) using secondary data. uk ms centers with national health service (nhs) databases and/or homecare and pharmacy services prescribing ofatumumab were identified and recruited for study participation using a feasibility assessment exercise. the study index identification window spanned from 26 march 2021 to 30 june 2023 (or latest data available prior to start of study data extraction). the index date was defined as the first date ofatumumab was dispensed or injected within the index identification window. from index date, patients were followed up until death, up to 13 months after index date, loss to follow-up, or end of study index identification window (whichever came first). for patients who consented to the use of their data, participating sites transcribed protocol required patient data from existing individual patient medical records into an electronic case report form (ecrf). the end of study was defined as the date of last data query resolution (i.e., all data had been recorded in the ecrf and all data queries resolved to allow database lock to occur). this ensured that all data was available to answer the research questions in the study.


Eligibility criteria:
inclusion criteria: patients were included in the study if they met all of the following criteria: * patient was prescribed ofatumumab within the uk approved marketing authorization * patient initiated ofatumumab via participating ms clinic with or without kc psp * patients initiated ofatumumab during the index identification window * authorized to collect study data: 1. patient was alive at start of data collection and patient consented prior to start of their data collection or, 2. patient was deceased at start of data collection and a member of the patient's direct care team had a pre-existing right to access patient medical record * specifically for adherence analyses: patients were required to have a minimum of 6 months of follow-up post index date available to make this assessment * specifically for clinical effectiveness analyses: patients were required to have a minimum of 6 months look-back pre-index date and minimum 6 months follow-up post index date available to make this assessment. exclusion criteria: patients were excluded from the study if they met the following criteria: • patient prescribed ofatumumab outside the approved marketing authorization (i.e., under off-label prescribing) at any point within the patients record

Keywords: disease modifying therapy medication adherence ofatumumab
comparison of the protective effect of desflurane and propofol in patients with renal transplantation

Conditions: Healthy; End Stage Renal Disease

Summary: ischemia/reperfusion (ir) injury is the major cause of early renal dysfunction and acute renal failure of the transplanted kidney after renal transplantation. in 1986, murry et al. described the phenomenon "ischemic preconditioning". also, it was reported that a few non-ischemic stimuli could provide cellular tolerance against major ischemia through a mechanism similar to ischemic preconditioning. in an animal study, 1 minimal alveolar concentration of volatile anesthetics - a clinically relevant concentration - was reported to have a protective effect against ischemia/reperfusion injury, the effect being variable between types of anesthetics. also, there were somm reports that intravenous anesthetics such as propofol could reduce ir injury by decreasing oxidative stress and apoptosis. by reducing the ischemia/reperfusion injury of the grafted kidney, the morbidity and mortality related to renal transplantation can be reduced as well. the objective of this study is to find out whether, according to the type of anesthetics (desflurane vs. propofol), there is a difference in the protective effect against ischemia/reperfusion injury of the grafted kidney in patients receiving renal transplantation.


Eligibility criteria:
inclusion criteria: * healthy kidney donors and their recipients of renal transplantation. exclusion criteria: * a donor that has any medical or surgical history, * a recipient that is scheduled to have any other surgery with renal transplantation surgery.

Keywords: healthy kidney donors and their recipients with end stage renal disease
effect of post isometric relaxation technique & eccentric muscle contraction on hamstring spasticity in cp

Conditions: Spastic Cerebral Palsy

Summary: cerebral palsy is a disorder of movement and posture due to deficit or lesion of immature brain. out of all types of cerebral palsy 77.4% is spastic cerebral palsy. spasticity is resistance to externally imposed movement increases with increasing speed of stretch and varies with the direction of joint movement. in this research the aim of our study is to measure the effects of post isometric relaxation and eccentric muscle energy technique of spasticity of hamstring muscle in cerebral palsy children in randomized controlled study. study duration is of six months. sampling will be lottery method. inclusion criteria will include individuals having age between five to fifteen with diplegic cerebal palsy, well oriented and spastic hamstrings with ashworth score +2 or +3.exclusion criteria includes children with flaccid and mixed cerebral palsy, quadriplegic and hemiplegic cerebral palsy and mentally retarded. data will be collected on structured questionnaire. those individuals who fulfill inclusion criteria will be divided into two groups .both groups will be treated with hot packs for ten minutes and static stretching. group 1 will be given post isometric relaxation technique and group 2 will be given eccentric muscle energy technique. post interventional analysis will be done at sixth week. data will be analysed with spss 21.

the primary purpose of this study is to investigate effects of eccentric isotonic contraction on on hamstring flexibility of cerebral palsy children,and to investigate effects of post isometric relaxation on on hamstring flexibility of cerebral palsy children.it is a randomized control trial. this study will be conducted in paf school for psn norkhan base rawalpindi. data collection time is from oct 2018- march 2019. sample size is 30 cp child,15 in each group calculated by open epi tool. ap per inclusion criteria only those participants will be included with age bracket 5-15 years,spastic diplegic , well oriented and on modified ashworth scale their score is +2 or +3. children with flaccid and mixed cerebral palsy,quadriplegic and hemiplegic cerebral palsy or mentally retarded will not be part of study. those patients who fulfill inclusion criteria are divided in to two groups. intervention will be provided and assessments should be done on 1st on baseline and then after 6 weeks.data collection tools will be gross motor functional scale,goniometry for measuring joint ranges and motor assessment scale for measuring their functional status.

Eligibility criteria:
inclusion criteria: * children with spastic cerebral palsy * diplegic cerebral palsy * well oriented * spastic hamstrings with ashworth score +2 or +3 exclusion criteria: * children with flaccid and mixed cerebral palsy * quadriplegic and hemiplegic cerebral palsy * mentally retarded

Keywords: cerebral palsy post isometric relaxation hamstring spasticity
plantar fasciitis and therapeutic ultrasound

Conditions: Plantar Fasciitis

Summary: the purpose of this study is to determine whether therapeutic ultrasound is effective in the treatment of plantar fasciitis (pf).

plantar fasciitis (pf) is the main cause of pain in the bottom of the heel. according to the american physical therapy association guidelines since 2008, many treatments have been described to correct the problem, but there are very few high level randomized trials that proved them. although not mentioned even in clinical treatment guidelines in pf, one of the most common conservative treatments for use, in general and israel in particular, is a therapeutic ultrasound device. despite this widespread use, there are very few research evidence which examining the effectiveness of this device for the treatment of pf. the purpose of this study is to evaluate the effect of therapeutic ultrasound versus sham ultrasound on pain, function and quality of life of patients with pf. our hypothesis is that the use of ultrasound parameters that cause an increase in the target tissue heat (from 1.75 to 1 w/cm2, continues intensity of 1 mhz) will result in a significant improvement than placebo. to evaluate this hypothesis, we will do a prospective, controlled, randomized, double-blind interventional clinical study. the study population will include 60 patients, aged 18 or older, suffering from pf and meet inclusion criteria. subjects will be divided randomly into study or control group, both groups will receive stretching instructions, when the study group will receive active ultrasound and the control group will receive sham ultrasound. both groups will receive 8 treatments, twice a week.

Eligibility criteria:
inclusion criteria: * worsening symptoms first steps in the morning or at the beginning of walking after sitting for long periods, and after long walking or standing. * pain at the bottom of the heel produced by weight bearing or local press. * pain level 3 or higher on nprs at first steps in the morning. * tenderness, swelling, or both in the region of proximal plantar fascia and at medial plantar tuberosity of the calcaneous. * gradual development of pain at the bottom of the heel. exclusion criteria: * peripheral neuropathy. * tarsal tunnel syndrome (tts) \\ fat pad syndrome (fps). * calcaneal cyst, fracture or bone cancer. * osteo arthritis (oa) of the foot fingers or rheumatoid arthritis (ra). * foot surgery at the last year. * steroid injections at the last six months. * pregnancy. * foot infection or diabetic foot. * stress fractures of the heel. * unavailability in advance to participate in research.

Keywords: therapeutic ultrasound, treatment, plantar fasciitis